West Nile Virus capsid protein causes encephalitic inflammation by triggering cell suicide

December 09, 2002

(Philadelphia, PA) - The protein that forms the protective capsid surrounding the West Nile virus genetic material may contribute to the deadly inflammation associated with the virus. West Nile virus, which has rapidly spread across the United States, causes neurological symptoms and encephalitis, which can result in paralysis or death. According to researchers at the University of Pennsylvania School of Medicine, the West Nile virus capsid (WNV-Cp) is a destructive protein that can trigger apoptosis - the automatic self-destructive program within cells - inside infected cells, possibly adding to the damage caused by the virus. Their findings are presented in the December issue of Emerging Infectious Diseases, a journal available on the Centers for Disease Control and Prevention (CDC) Web site.

"Despite the fact that West Nile virus is a global health threat, we understand very little of the pathogenesis of the disease caused by this virus," said David Weiner, PhD, associate professor in Penn's Department of Pathology and Laboratory Medicine. "Since there is currently no specific treatment for West Nile virus, it is important to understand the biology of this virus to help us devise vaccines and new treatments for the West Nile virus infection."

According to the CDC, the West Nile virus has infected over 3700 people and killed over 200, mostly elderly, people since it was first introduced to the United States in 1999. The numbers of those infected, however, may be much higher since the disease often takes a mild form in healthy people who are less likely to seek treatment and the CDC numbers only count for those cases known to state medical agencies. The virus is spread primarily through its insect host, the mosquito, although it is now known to spread through mothers' breast milk and organ transplantations.

The Penn researchers first began studying WNV-Cp when they noticed a striking similarity between the gene that encodes for it and that of an HIV regulatory protein. "We hope to extend the lessons they have learned in trying to develop therapeutics for HIV in fighting West Nile." Said Weiner. "In addition to the possibility of creating a vaccine for West Nile, our results support the idea that a specific portion of the capsid protein - called the 3' terminal region - is required for the protein's pathogenicity. If we can find a way to block that region's function, this might help slow the virus down."

By itself, the WNV-Cp protein can cause inflammation. Weiner and his colleagues found that WNV-Cp drives apoptosis in cell cultures through what is called the mitochondrial pathway. The protein begins the process of cell suicide by somehow disrupting the membrane potential of the cell's mitochondria, which then leads to the activation of proteins such as caspase-9 and caspase-3 that start a cascade of reactions to subsequently cause the cell to digest itself.

Since the protein enters the nucleus of the cell, it is possible that WNV-Cp changes the host cell's transcriptional machinery, resulting in an over production of certain proteins related to an apoptotic program, which consequently feed back to the mitochondria.

Alternatively, as WNV-Cp moves from the cytoplasm to the nucleus, it may inactivate an important part of the cell's natural control system that keeps apoptosis in check - overpowering the guard as it were - thus inducing the cell suicide.

"Overall, our data suggest that WNV-Cp may interact with host cell proteins to induce apoptosis in the host cell," said Weiner, "Identifying these proteins will likely give more insight into the biology of West Nile."

The proteins pathogenic properties extend outside of the tissue culture. WNV-Cp also directly caused apoptosis and inflammation in mouse muscle cells. More importantly, the WNV-Cp protein caused inflammation and apoptosis in mouse brain in a manner similar to what is observed in natural infections.
-end-


University of Pennsylvania School of Medicine

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.